<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076960</url>
  </required_header>
  <id_info>
    <org_study_id>99A</org_study_id>
    <nct_id>NCT00076960</nct_id>
    <nct_alias>NCT01183988</nct_alias>
  </id_info>
  <brief_title>Compassionate Use of Stanate (TM) [Stannsoporfin]</brief_title>
  <official_title>Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to make Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
      available to infants who meet the following criteria:

        1. the infant has a very high level of bilirubin without an adequate clinical response to
           phototherapy;

        2. the infant requires an exchange transfusion; and

        3. the family refuses to allow the administration of blood products, particularly on
           religious grounds, such as within the Jehovah's Witness community.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <condition>Neonatal Jaundice</condition>
  <condition>Hyperbilirubinemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stanate (TM) [stannsoporfin, tin-mesoporphyrin]</intervention_name>
    <description>Treatment with 4.5 mg/kg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Term or near term neonate

          -  Elevated serum bilirubin

          -  Failing phototherapy

          -  Requires exchange transfusion

          -  Family refuses exchange transfusion on religious grounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Week</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kappas A, Drummond GS, Munson DP, Marshall JR. Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion. Pediatrics. 2001 Dec;108(6):1374-7.</citation>
    <PMID>11731664</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2004</study_first_submitted>
  <study_first_submitted_qc>February 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2004</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperbilirubinemia</keyword>
  <keyword>jaundice</keyword>
  <keyword>tin-mesoporphyrin</keyword>
  <keyword>stannsoporfin</keyword>
  <keyword>exchange transfusion</keyword>
  <keyword>neonatal hyperbilirubinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Jaundice, Neonatal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

